Talzenna Plus Xtandi May Improve Survival in Metastatic Castration-Resistant Prostate Cancer by admin_63069 | Mar 17, 2025 | News You Can Use Patients with HRR-deficient metastatic castration-resistant prostate cancer experienced a 14-month gain in OS and a 38% lower death risk with Talzenna plus Xtandi.